Product Description
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous,Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Pakistan
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Prostatitis
Phase 3: Sepsis|Chronic Obstructive Pulmonary Disease|Acquired Immunodeficiency Syndrome|Tuberculosis, Pulmonary|HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| OptiRiMoxTB | P3 |
Recruiting |
Acquired Immunodeficiency Syndrome|HIV Infections|Tuberculosis, Pulmonary |
2025-12-31 |
2023-08-27 |
||
| COPD | P3 |
Completed |
Chronic Obstructive Pulmonary Disease |
2020-08-30 |
2024-11-27 |
||
| FIRST | N/A |
Completed |
Colitis|Clostridium Infections |
2024-05-31 |
2025-02-01 |
Primary Endpoints |
|
| ChiCTR2200059983 | N/A |
Not yet recruiting |
Colorectal Cancer |
2024-04-30 |
2023-03-19 |
Treatments |
|
| ChiCTR2300072349 | N/A |
Not yet recruiting |
Sepsis |
2024-04-15 |
2023-06-14 |
||
| N2113 | N/A |
Completed |
Communicable Diseases|Urinary Tract Infections |
2020-09-30 |
2021-01-29 |
Primary Endpoints|Treatments |
|
| CR108484 | N/A |
Completed |
Sinusitis|Bronchitis|Urinary Tract Infections |
2018-12-31 |
2019-03-22 |
Patient Enrollment|Treatments|Trial Status |
|
| Lactorepens® | P4 |
Completed |
Prostatitis |
2012-12-01 |
2019-03-20 |
||
| 04/UR/08-20 | P3 |
Completed |
Chronic Obstructive Pulmonary Disease|Sepsis |
2005-06-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| STOPCANCER | N/A |
Recruiting |
Urogenital Cancer|Prostate Cancer |
None |
2024-04-03 |
Treatments |